Why Heron Therapeutics Stock Popped in July

Shares of Heron Therapeutics (NASDAQ: HRTX), a small-cap drugmaker, gained 10.7% over the course of July, according to data provided by S&P Global Market Intelligence. In late June, Heron's stock took a big step backward in response to a Complete Response Letter from the Food and Drug Administration (FDA) for its non-opioid painkiller Zynrelef, also known as HTX-011. As this rejection reportedly centered around four non-clinical issues, the biotech should be able to get this all-important regulatory application back on track in short order.